Mandate

Vinge advises PPR S.A in connection with the sale of Ellos and Jotex

February 25, 2013

Vinge has advised PPR S.A in connection with the sale of Ellos and Jotex to Nordic Capital Fund VII for an enterprise value of €275 million. Ellos is the leading home shopping player in Scandinavia for apparel and Jotex has established itself as a key player in the Scandinavian home textile and decoration market.

PPR S.A is one of the world’s leading apparel and accessories groups that operates in the two fastest growing market segments: Luxury and Sport & Lifestyle. The PPR Group has built a balanced collection of complementary consumer brands, including for example Gucci, Bottega Veneta, Saint Laurent, Alexander McQueen, Stella McCartney, Sergio Rossi, Girard-Perregaux, Puma and Tretorn. Present in more than 120 countries, the PPR Group generated revenues of €9.7 billion in 2012 and had over 33,000 employees at year end. The PPR share is listed on Euronext Paris.

The transaction is subject to approval of relevant competition authorities.

Vinge’s team consisted of responsible partner Johan Winnerblad together with, among others, Christina Kokko (partner) and associates Joacim Rydergård, Alex Miler, Eric Ödling, Karl Hahtovirta and project assistant Annika Johnson.

 

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026